March 3 (Reuters) - Bharat Biotech:
* BHARAT BIOTECH ANNOUNCES PHASE 3 RESULTS OF COVAXIN, COVID-19 VACCINE DEMONSTRATES INTERIM CLINICAL EFFICACY OF 81%
* SAYS COVID-19 VACCINE DEMONSTRATES INTERIM CLINICAL EFFICACY OF 81%
* COVAXIN DEMONSTRATED 81% INTERIM EFFICACY IN PREVENTING COVID-19 IN THOSE WITHOUT PRIOR INFECTION AFTER SECOND DOSE
* DATA FROM 25,800 PARTICIPANTS, RECEIVED A VACCINE OR PLACEBO IN A 1:1 RATIO SHOWED THAT THE VACCINE CANDIDATE WAS WELL TOLERATED
* CLINICAL TRIAL TO CONTINUE THROUGH TO FINAL ANALYSIS AT 130 CONFIRMED CASES IN ORDER TO GATHER FURTHER DATA Source text: (https://bit.ly/3qfqGge)
Our Standards: The Thomson Reuters Trust Principles.
